Crescent Biopharma, Inc. (CBIO)
NASDAQ · Manufacturing · Pharmaceutical preparations
CBIO price, last 12 months
Key stats
- Previous close
- $12.40
- Open
- $12.50
- Day range
- $12.17 – $13.19
- 52-week range
- $8.72 – $27.41
- Volume
- 262.1K
- Avg volume (20 days)
- 243.6K
- Market cap
- $591.3M
Performance
Technicals and fundamentals
About Crescent Biopharma, Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $591.3M